fda warning letter compounded semaglutide september 2025 letters glp-1 Fda Warning Letters Glp-1 Compounded September 2025 There's lots going on this month at FDA Maybe i’m not against compounding

New Kid on the Block - Retatrutide for Obesity Management Kimmy Nguyen Dec 10, 2025 6 min read Written by Mariana Lopez, PharmD Candidate 2026 and Adenike Atanda-Oshikoya PharmD, BCACP, CDCES, CTTS Background on Obesity and Comorbidities Obesity, as defined by the World Health Organization (WHO), is the excessive and unhealthy accumulation of body fat.(1) Severe obesity is strongly associated with comorbid conditions such as type 2 diabetes mellitus (T2DM), cardiovascular disease (CVD), heart failure, chronic liver disease, and reduced life expectancy.(2) In addition to the clinical implications, obesity poses a substantial economic burden

It is a chronic condition driven in large part by hormonal and neurological systems that the body uses to defend its weight

They also have endometriosis

Ethics declarations Competing interests MRH receives funding from Zealand Pharma and Novo Nordisk that was not used in support of these studies

After the ultrasound, the mixture was centrifuged at 10,000 rpm for 510 min to obtain the NPs precipitate